OTC:CVSI
CV Sciences, Inc.
CV Sciences leverages proprietary imaging technology to provide advanced clinical solutions for hospitals and surgical centers.
Key Metrics
Investment Thesis
Bull Case
Investors might buy CVSI for its potential as a turnaround story given its substantial paid-in capital and proven technology stack that differentiates it from commodity hardware providers. The shift to profitability in 2023 suggests management can control burn rates, and the recurring nature of service contracts offers a path to stable cash flows once growth stabilizes. At current OTC valuations, the stock may offer significant upside if the company successfully executes its strategy to expand market share.
Bear Case
The stock carries high risk due to consecutive years of negative net income and a massive $87M deficit in retained earnings that threatens long-term solvency. Operating cash flow is severely negative, indicating the business model may not yet be self-sustaining without external financing or significant revenue growth. The OTC listing status combined with declining revenue trends suggests limited analyst coverage and potential liquidity issues for shareholders.
About CV Sciences, Inc.
CV Sciences, Inc. (CVSI) is a medical technology company specializing in developing and commercializing innovative imaging solutions and software for clinical environments. The company serves hospitals, ambulatory surgery centers, and other healthcare facilities with its proprietary platform designed to enhance diagnostic capabilities and operational efficiency. Revenue streams primarily derive from the sale of hardware devices, licensing of intellectual property, and related support services within the competitive medical device market.
Analysis
Management Discussion
The company reported revenue of $15.7M in 2024, a slight decline from prior years, while posting a net loss of $2.4M following a profitable period in 2023. Cash flow from operations turned negative at -$861K, driven by working capital changes and the need to fund ongoing R&D and general administrative expenses totaling $9.4M. Despite these challenges, the company maintains a strong paid-in capital base of $88.8M, though the net change in cash was negative, reducing ending cash to $454K.
Industry Overview
The medical imaging industry is characterized by rapid technological innovation driven by artificial intelligence and the demand for lower-dose, high-resolution diagnostics. While dominated by large incumbents like GE HealthCare and Siemens, there is a growing niche for specialized vendors offering cost-effective, software-defined solutions tailored to specific clinical needs. Regulatory scrutiny remains high, with approval processes for new devices taking years and requiring substantial investment in clinical trials.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $16.2M | $16.0M | $15.7M |
| Cost of Revenue | $10.7M | $8.9M | $8.5M |
| Gross Profit | $5.5M | $7.1M | $7.2M |
| Operating Expenses | $12.4M | $3.7M | $9.4M |
| Operating Income | $-6.8M | $3.4M | $-2.2M |
| R&D | $307.0K | $151.0K | $118.0K |
| G&A | $12.1M | $9.7M | $4.0M |
| Stock-Based Comp | $1.0M | $218.0K | $258.0K |
| D&A | $992.0K | $235.0K | $334.0K |
| Depreciation | $1.0M | $200.0K | $300.0K |
| Amortization | — | $1.0K | $21.0K |
| Other OpEx | $0 | $-6.2M | $5.3M |
| Non-Operating Income | $-1.4M | $-264.0K | $-212.0K |
| Pre-Tax Income | $-8.3M | $3.1M | $-2.4M |
| Income Tax | $-47.0K | $-6.0K | $-8.0K |
| Continuing Ops | $-8.2M | $3.1M | $-2.4M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-8.2M | $3.1M | $-2.4M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-8.2M | $3.1M | $-2.4M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $11.1M | $7.9M | $6.2M |
| Cash & Equivalents | $611.0K | — | — |
| Accounts Receivable | $766.0K | $431.0K | $522.0K |
| Inventory | $6.6M | $5.7M | $4.9M |
| Prepaid Expenses | — | $535.0K | $370.0K |
| Other Current Assets | $3.2M | $1.3M | $454.0K |
| Long-Term Assets | $1.6M | $1.3M | $1.7M |
| PP&E (Net) | $575.0K | $379.0K | $399.0K |
| Intangibles | — | $78.0K | $93.0K |
| Goodwill | $0 | $342.0K | $971.0K |
| Operating Leases | $275.0K | $167.0K | $94.0K |
| Other LT Assets | $756.0K | $296.0K | $127.0K |
| Total Assets | $12.7M | $9.2M | $7.9M |
| Current Liabilities | $13.3M | $6.1M | $6.1M |
| Accounts Payable | $2.3M | $2.3M | $1.9M |
| Current Leases | $117.0K | $130.0K | $83.0K |
| Other Current Liab | $1.2M | $254.0K | $677.0K |
| Long-Term Liabilities | $199.0K | $182.0K | $23.0K |
| LT Operating Leases | $188.0K | $58.0K | $19.0K |
| Other LT Liab | $11.0K | $124.0K | $4.0K |
| Total Liabilities | $13.5M | $6.3M | $6.1M |
| Shareholders' Equity | $-777.0K | $2.9M | $1.8M |
| Paid-In Capital | $86.9M | $87.5M | $88.8M |
| Retained Earnings | $-87.7M | $-84.6M | $-87.0M |
| AOCI | — | $10.0K | $-15.0K |
| Total L&E | $12.7M | $9.2M | $7.9M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-8.2M | $3.1M | $-2.4M |
| Non-Cash Adjustments | $12.3M | $3.8M | $3.2M |
| Working Capital Changes | $-6.0M | $-4.6M | $-1.6M |
| Cash from Operations | $-1.9M | $2.3M | $-861.0K |
| Capital Expenditures | $0 | — | $18.0K |
| Cash from Investing | $0 | $-156.0K | $-28.0K |
| Cash from Financing | $1.1M | $-1.4M | $32.0K |
| FX Effect | $0 | $0 | $-6.0K |
| Net Change in Cash | $-764.0K | $706.0K | $-863.0K |
| Beginning Cash | $1.4M | $611.0K | $1.3M |
| Ending Cash | $611.0K | $1.3M | $454.0K |
Frequently Asked Questions
How does CV Sciences, Inc. make money?
Hardware sales of imaging systems; Licensing of core intellectual property and software platforms; After-market service agreements and maintenance contracts; International distribution and partnership revenues.
What are the main risks for CVSI?
Significant operating losses and a substantial retained earnings deficit of $87M indicating potential liquidity constraints; High customer concentration risk where a loss of a few key clients could materially impact revenue; Intense competition from larger medical device giants offering lower-priced alternatives; Regulatory changes or delays in reimbursement rates that could suppress demand for advanced imaging.
What is CVSI's competitive advantage?
Proprietary image reconstruction algorithms that deliver high-quality diagnostic data with reduced radiation exposure; Established relationships with major hospital systems ensuring recurring service revenue; A scalable software architecture that allows for rapid deployment across diverse clinical workflows.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.